Wellbutrin and Prozac Together: What to Know About Combining Bupropion and Fluoxetine
Author:
Blossom Editorial
Taking Wellbutrin and Prozac together is one strategy clinicians may consider when an antidepressant has produced a partial response or when there is another reason to add a medication with a different side-effect and pharmacologic profile. The two medications target different brain chemicals, which is one of the reasons why they may be paired in certain cases.
Although starting two antidepressants at the same time is generally less well supported by the evidence, adding an adjunctive medication to an existing one is sometimes considered. Augmenting Prozac with Wellbutrin is one approach that has been studied, though there are a few specific risks worth understanding beforehand. Here is what the evidence shows.
Key Takeaways
The two medications target different systems: Prozac (fluoxetine) affects the serotonin system, while Wellbutrin (bupropion) acts on dopamine and norepinephrine. Because the medications have different pharmacologic effects and side-effect profiles, providers may consider augmenting Prozac with Wellbutrin in certain cases of partial response or to reduce antidepressant side effects.
The research is encouraging but not conclusive: Open-label studies suggest Wellbutrin added to an SSRI antidepressant (e.g., fluoxetine) can help people who did not fully respond to one medication. The largest randomized trial, however, found the combination no better than an SSRI alone across the whole group.
Two safety issues need attention: Wellbutrin lowers the seizure threshold and also inhibits the liver enzyme that clears fluoxetine, which may raise fluoxetine levels. The combination can usually be managed with conservative dosing and monitoring, but neither effect should be ignored.
Why Prescribers Combine Wellbutrin and Prozac
Many people who start an antidepressant do not reach full remission on the first try. Some symptoms lift while others remain. Residual symptoms can include fatigue, low motivation, difficulty concentrating, sleep problems, or other depressive symptoms. Some people also experience sexual side effects from antidepressant treatment.
Such partial response is one reason why Wellbutrin (bupropion) is an appealing addition. Wellbutrin is a norepinephrine and dopamine reuptake inhibitor (NDRI), and it doesn’t substantially impact serotonin, which is the main neurotransmitter that SSRI and SNRI antidepressants target. It works by inhibiting the reabsorption of norepinephrine and dopamine into nerve cells, resulting in increased availability of these chemicals in certain regions of the brain.
Norepinephrine and dopamine both help regulate several brain functions. Norepinephrine is involved in alertness and attention, while dopamine plays a role in motivation, reward, and attention. Although the exact mechanism isn’t fully understood, changes in these neurotransmitters are thought to result in antidepressant effects.
Prozac (fluoxetine), by contrast, is an SSRI antidepressant. It blocks serotonin reabsorption, leaving more of this neurotransmitter available between nerve cells. The resulting changes in serotonin signaling help improve mood over time.
Because these mechanisms do not overlap, prescribers sometimes describe the combination as covering complementary territory rather than simply intensifying one effect.
What the Research Says About Combining Bupropion and an SSRI
The evidence here is mixed, and it is worth looking at both the supportive and the skeptical findings rather than just one.
Studies Supporting Bupropion Augmentation
A 2006 review published in Biological Psychiatry surveyed the literature on adding bupropion (Wellbutrin) to an SSRI or SNRI. It concluded that controlled and open-label studies support bupropion’s ability to reverse antidepressant-related sexual dysfunction, and that open trials suggest the combination helps people whose depression did not respond adequately to either medication alone.
In a small preliminary study from 2002, adding bupropion SR (Wellbutrin-sustained release) for 8 weeks to ongoing treatment (having completed at least 6 weeks) with fluoxetine, paroxetine, or venlafaxine was associated with clinically significant improvement in most participants, as well as improvements in some measures of sexual dysfunction. However, the study was small and was not designed to evaluate the fluoxetine–bupropion combination separately.
An earlier case series from Harvard-affiliated clinicians reviewed 27 outpatients who had only partially responded to a serotonin reuptake inhibitor or to bupropion by itself. Roughly 70% showed greater improvement on the combination than on either medication alone, with adverse effect rates similar to what each drug produces individually. This was a small, uncontrolled study, so it suggests a direction rather than proving one.
The 2023 OPTIMUM trial provides more recent evidence for Wellbutrin (bupropion) augmentation, although it did not specifically study the Prozac-Wellbutrin combination. In this trial of adults aged 60 and older with treatment-resistant depression, participants continued their existing antidepressant and added bupropion. Notably, over 28% achieved remission over approximately 10 weeks, compared with over 19% of those who switched from their existing antidepressant to bupropion. Because participants remained on various existing antidepressants, the findings support bupropion augmentation broadly.
Study on Combined Treatment
Research on starting bupropion (Wellbutrin) and an SSRI at the same time has produced mixed results. The CO-MED trial compared the SSRI escitalopram (Lexapro) alone with two antidepressant combinations in 665 adults with chronic or recurrent major depressive disorder. Of the two combinations studied, one paired escitalopram with sustained-release bupropion. Neither combination produced a higher remission rate than escitalopram alone, suggesting that starting two antidepressants simultaneously did not provide a clear benefit over monotherapy in this population. A later secondary analysis found that BMI moderated outcomes, but this finding should be considered exploratory rather than a general treatment rule.
The practical takeaway is nuanced. Starting two antidepressants at the beginning of treatment has not consistently outperformed antidepressant monotherapy. Adding bupropion after a partial response is a different strategy. Current guidelines consider adjunctive bupropion an option for some people with an incomplete response, although the overall evidence is mixed and less robust than for some other adjunctive treatments.
Common Reasons This Combination Gets Prescribed
In practice, a few specific scenarios support augmentation with Wellbutrin. Each has a different rationale behind it.
Partial Response to Prozac Alone
When Prozac has clearly helped, but symptoms have plateaued short of remission, prescribers face a choice: raise the dose, switch to something else, or add a second medication. Adding Wellbutrin may preserve whatever benefit Prozac has already delivered while introducing a different mechanism.
Persistent Fatigue and Low Motivation
Some depressive symptoms may respond poorly to serotonin alone. Low energy or motivation and reduced interest can persist even when other symptoms improve. Wellbutrin’s different pharmacologic profile is one reason clinicians may consider it when these symptoms remain, since its effect on norepinephrine and dopamine can be activating in some people.
SSRI-Related Sexual Side Effects
This may be the better-supported use of the combination. Sexual side effects are common with SSRIs, including Prozac, and they are a leading reason people stop taking antidepressants. Wellbutrin is one of the medications that has been studied as a treatment for antidepressant-induced sexual dysfunction. Some randomized studies suggest it can improve sexual functioning, although results can vary.
Safety Considerations With Wellbutrin and Prozac
Two specific interactions between these medications deserve real attention. Neither rules out the combination, but both shape how it is dosed and monitored.
Seizure Risk
Wellbutrin lowers the seizure threshold, and the risk rises with higher doses. The FDA prescribing information for Wellbutrin XL contraindicates the medication in people with a seizure disorder, in people with a current or prior diagnosis of bulimia or anorexia nervosa, and in people abruptly stopping alcohol, benzodiazepines, barbiturates, or antiseizure medications.
Wellbutrin should also be used cautiously alongside other medications that lower the seizure threshold, a category that includes antidepressants generally. In practice, this usually means starting Wellbutrin at a low dose and spacing increases out. You should always share your complete medical history with your provider, including medications, past head injury, and a history of seizures or eating disorders.
The CYP2D6 Interaction
This is another important interaction to watch out for. Wellbutrin strongly inhibits the CYP2D6 enzyme, which can affect the levels of medications that rely on this enzyme for metabolism. The FDA label lists fluoxetine (Prozac) among the medications whose concentrations may be affected. However, because fluoxetine has complex metabolism and is itself a strong CYP2D6 inhibitor, the clinical significance of this interaction can vary. A prescriber should review the full medication regimen when these drugs are used together.
Serotonin Syndrome
Serotonin syndrome is primarily a risk when multiple serotonergic (serotonin-regulating) medications are combined. Wellbutrin does not act meaningfully on serotonin, so it is not generally considered a strongly serotonergic antidepressant. However, Prozac and any other serotonergic medications in the regimen can still contribute to serotonin syndrome risk. If you are taking other medications that raise serotonin, including certain migraine treatments, pain medications, or supplements, your prescriber will want a complete list.
What Side Effects to Expect
When you take two antidepressants, you can experience side effects from either one. Some overlap and some pull in opposite directions.
Effects associated more with Wellbutrin:
Insomnia, particularly if the dose is taken later in the day
Dry mouth
Nausea
Jitteriness or feeling wired
Headache
Reduced appetite
Increased blood pressure in some people
Tremors
Sweating
Effects associated more with Prozac:
Nausea, especially during the first weeks
Dry mouth
Anxiety
Tremors
Sexual side effects
Drowsiness or fatigue in some people, and insomnia in others
Sweating
Changes in appetite
Both Wellbutrin and Prozac can contribute to insomnia, anxiety, or restlessness in some people. Taking them together does not necessarily mean these side effects will become more severe, although some overlapping effects may be more noticeable. In cases where Wellbutrin is added after an adequate Prozac trial, many of the early side effects of Prozac, such as nausea, anxiety, headache, or fatigue, may already have improved. Adding Wellbutrin may also help reduce SSRI-associated sexual side effects for some people. Even so, the benefits and side effects of the combination can vary from person to person.
Wellbutrin is often taken earlier in the day to reduce the chance of insomnia. The best time to take Prozac, however, can vary depending on how it affects the individual. Your provider can adjust the timing of your medication based on your response.
Both medications carry an FDA boxed warning about an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants. Close monitoring is particularly important during the first months of treatment and when the dose is changed, but new or worsening suicidal thoughts should be taken seriously at any time.
How Long Before You Know If It Is Working
Adding Wellbutrin (bupropion) to Prozac (fluoxetine) tends to follow a similar timeline to starting an antidepressant. Some people notice a shift in energy, sleep, appetite, or side effects within the first one to two weeks, although improvements in mood can take longer.
The fuller picture generally takes 6-8 weeks at a stable dose, and prescribers often wait closer to eight weeks before concluding that the combination is not delivering. If sexual side effects were the target, improvement may appear within a few weeks.
Questions Worth Asking Your Prescriber
If this combination is on the table, a few questions can help you get oriented:
What specific symptoms are we hoping Wellbutrin will address?
Would raising the Prozac dose or switching medications accomplish the same thing with less complexity?
Do I have any history that raises my seizure risk?
Which formulation of Wellbutrin are we using, and at what starting dose?
How long should we give this before deciding whether it worked?
What should I watch for, and when should I call rather than wait for the next appointment?
Persistent or returning symptoms do not necessarily mean that an antidepressant dose is too low. A prescriber can help determine whether dose adjustment, a different treatment strategy, or another factor may explain the symptoms.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always talk with your physician or another qualified healthcare provider about any questions regarding a medical condition or medication. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
U.S. Food and Drug Administration. (2025). Wellbutrin XL (bupropion hydrochloride extended-release) tablets, for oral use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021515s049lbl.pdf
U.S. Food and Drug Administration. (2025). Wellbutrin SR (bupropion hydrochloride) sustained-release tablets, for oral use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020358s070lbl.pdf
U.S. Food and Drug Administration. (2017). Prozac (fluoxetine hydrochloride) capsules, for oral use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2024 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/
Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459223/
Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/
Rush, A. J., Trivedi, M. H., Stewart, J. W., et al. (2011). Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. The American journal of psychiatry, 168(7), 689–701. https://pubmed.ncbi.nlm.nih.gov/21536692/
Zisook, S., Rush, A. J., Haight, B. R., Clines, D. C., & Rockett, C. B. (2006). Use of bupropion in combination with serotonin reuptake inhibitors. Biological psychiatry, 59(3), 203–210. https://pubmed.ncbi.nlm.nih.gov/16165100/
Kennedy, S. H., McCann, S. M., Masellis, M., McIntyre, R. S., Raskin, J., McKay, G., & Baker, G. B. (2002). Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. The Journal of clinical psychiatry, 63(3), 181–186. https://pubmed.ncbi.nlm.nih.gov/11926715/
Bodkin, J. A., Lasser, R. A., Wines, J. D., Jr, Gardner, D. M., & Baldessarini, R. J. (1997). Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. The Journal of clinical psychiatry, 58(4), 137–145. https://pubmed.ncbi.nlm.nih.gov/9164423/
Lenze, E. J., Mulsant, B. H., Blumberger, D. M., OPTIMUM Collaborative Group, et.al. (2023). Antidepressant augmentation versus switch in treatment-resistant geriatric depression. The New England Journal of Medicine, 388(12), 1067–1079. https://www.nejm.org/doi/full/10.1056/NEJMoa2204462
Lam, R. W., Kennedy, S. H., Adams, C.,et al. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 69(9), 641–687. https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/
Safarinejad, M.R. (2010).The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. BJU International, 106(6), 840-847. https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2009.09154.x
National Institute of Mental Health. (n.d.). Mental health medications. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/mental-health-medications
